Dr Emma Nolan
Generation of a preclinical model that is more representative of breast cancer in our population, to inform patient stratification and preclinical evaluation of novel therapeutics and improve drug development pipelines.
Computational pathology (CPATH)/Computer Assisted Diagnosis research in breast cancer.
Dr Gavin Harris
To incorporate additional functionality into a prototype algorithm. Validation and training of the algorithm to assess risk of recurrence to enable de-escalation and escalation of treatment which may involve assessment against a gene expression profiling.
Targeting the Trop-2 glycoprotein for localised prodrug activation in breast cancer
Associate Professor Allan Gamble
In 2021, Sacituzumab Govitecan received accelerated approval by the FDA as a treatment for patients with unresectable metastatic triple negative breast cancer (TNBC). However, over half of all patients receiving this treatment still report significant side effects.
Exploring a preventative treatment through an existing and accessible drug for High-Risk Individuals
Dr George Wiggins
Women at high-risk of breast cancer are in need of new and effective prevention strategies.
Extracellular Vesicles as Inter-Cellular Communicators in Fat Graft Retention
Dr Kirsty Danielson
Breast reconstruction is an important part of the treatment process for women with breast cancer.
Stopping Breast Cancer Evolution: Evaluation of APOBEC3 Inhibitors in Live Cells
Associate Professor Vyacheslav Filichev
Drug resistance is a serious barrier to the treatment of breast cancer, leading to metastasis and cancer reoccurrences.
Exploring a Novel Therapy to Reduce Breast Cancer Risk in High-risk Individuals
Dr Vanessa Lattimore
The ideal strategy for controlling and reducing the social impact of disease is effective prevention.
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Dr Gavin Harris
Digital pathology is the reviewing of tissue slides on a computer monitor rather than using microscopes.
Validation Of Predictive Biomarkers For T-DM1 Activity In HER2+ Breast Cancer
Dr Barbara Lipert
The antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) extends the survival of HER2-positive metastatic breast cancer patients.
Analysis Of Full-length Transcripts For Variant Classification In Breast Cancer
Dr Logan Walker
The future of successful genetic screening in New Zealand requires increased sensitivity and specificity of tests, and informed clinical management for high-risk breast cancer families.